恩格列净对肾脏和全身血液动力学的影响：三项随机、双盲、安慰剂对照交叉试验

medRxiv - Nephrology Pub Date : 2024-05-29 DOI:10.1101/2024.05.28.24308079

Steffen Flindt Nielsen, Camilla Lundgreen Duus, Niels Henrik Buus, Jesper Nørgaard Bech, Frank Holden Mose

{"title":"恩格列净对肾脏和全身血液动力学的影响：三项随机、双盲、安慰剂对照交叉试验","authors":"Steffen Flindt Nielsen, Camilla Lundgreen Duus, Niels Henrik Buus, Jesper Nørgaard Bech, Frank Holden Mose","doi":"10.1101/2024.05.28.24308079","DOIUrl":null,"url":null,"abstract":"<strong>Background</strong> Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve renal outcomes in type 2 diabetes mellitus (DM2) and chronic kidney disease (CKD). A decrease in renal blood flow (RBF) with attenuation of glomerular hyperfiltration may contribute to this. We examined renal and systemic hemodynamic effects of SGLT2i in relevant patient categories.","PeriodicalId":501513,"journal":{"name":"medRxiv - Nephrology","volume":"22 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Renal and systemic hemodynamic effects of empagliflozin: Three randomized, double blind, placebo controlled cross-over trials\",\"authors\":\"Steffen Flindt Nielsen, Camilla Lundgreen Duus, Niels Henrik Buus, Jesper Nørgaard Bech, Frank Holden Mose\",\"doi\":\"10.1101/2024.05.28.24308079\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Background</strong> Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve renal outcomes in type 2 diabetes mellitus (DM2) and chronic kidney disease (CKD). A decrease in renal blood flow (RBF) with attenuation of glomerular hyperfiltration may contribute to this. We examined renal and systemic hemodynamic effects of SGLT2i in relevant patient categories.\",\"PeriodicalId\":501513,\"journal\":{\"name\":\"medRxiv - Nephrology\",\"volume\":\"22 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Nephrology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.05.28.24308079\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.05.28.24308079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

背景钠-葡萄糖共转运体 2 抑制剂（SGLT2i）可改善 2 型糖尿病（DM2）和慢性肾脏病（CKD）患者的肾脏预后。肾血流量（RBF）的减少以及肾小球高滤过率的减弱可能是原因之一。我们研究了 SGLT2i 在相关患者类别中对肾脏和全身血液动力学的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Renal and systemic hemodynamic effects of empagliflozin: Three randomized, double blind, placebo controlled cross-over trials

Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve renal outcomes in type 2 diabetes mellitus (DM2) and chronic kidney disease (CKD). A decrease in renal blood flow (RBF) with attenuation of glomerular hyperfiltration may contribute to this. We examined renal and systemic hemodynamic effects of SGLT2i in relevant patient categories.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

medRxiv - Nephrology

自引率

0.00%

发文量